Proteinase activated receptor‐2 counterbalances the vascular effects of endothelin‐1 in fibrotic tight‐skin mice
- 5 October 2016
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (22) , 4032-4042
Abstract
Background and Purpose: The majority of the severe vascular complications in fibrosis are a consequence of a deregulated activity of mediators controlling vasomotor tone. One of the most important of these mediators is endothelin‐1 (ET‐1). Here, we have investigated the role of proteinase‐activated receptor 2 (PAR2) in the vascular dysfunction in a model of fibrosis, using tight‐skin (Tsk) mice.Experimental Approach: Aortas were collected from Tsk, transgenic over‐expressing PAR2 (TgPAR2), PAR2 deficient (PAR2−/−) or the corresponding WT mice. Histological and immunohistochemistry analysis for α‐smooth muscle actin, PAR2 and ET‐1 receptors were performed on aorta sections. Vascular responses to phenylephrine, ET‐1 and PAR2 activating peptide (PAR2‐AP) were assessed on aortic rings.Key Results: In aortas from Tsk mice, responses to phenylephrine were reduced, contractions to ET‐1 were increased and vasorelaxation to PAR2‐AP was enhanced. These alterations matched changes observed in whole vessel architecture such as vascular fibre re‐organization, increased collagen deposition and enhanced α‐smooth muscle actin expression. Expression of both ETAreceptors and PAR2 was enhanced in Tsk mice. Antagonism of PAR2 potentiated vascular effects of ET‐1, whereas antagonism of ETAreceptors increased vasorelaxation induced by PAR2‐AP. In TgPAR2 mice, responses to ET‐1 and ET‐1 plasma levels were reduced. Conversely, PAR2−/−mice showed enhanced ET‐1 induced contraction in aortic rings and higher circulating ET‐1 levels.Conclusions and Implications: Our data show that PAR2 counterbalanced enhanced contractions to ET‐1 in aortas from Tsk mice. PAR2 could represent a possible target for novel drugs in the treatment of vascular complications in fibrosis.Linked Articles: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visithttp://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetocandhttp://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetocKeywords
This publication has 49 references indexed in Scilit:
- Deciphering the pro‐fibrotic phenotype of fibroblasts in systemic sclerosisExperimental Dermatology, 2014
- The Interaction of Endothelin-1 and TGF-β1 Mediates Vascular Cell RemodelingPLOS ONE, 2013
- Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia ModelPLOS ONE, 2013
- Bosentan fosters microvascular de-remodelling in systemic sclerosisClinical Rheumatology, 2012
- Role of protease-activated receptors in human skin fibrosis and sclerodermaExperimental Dermatology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptorsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosisRheumatology, 2007
- Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and α1-adrenoceptor-mediated vasoconstriction in Type 2 diabetesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Tight-Skin Mouse an Experimental Model for SclerodermaInternational Reviews of Immunology, 1994